| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.16 | 0.3 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |